Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Esophageal Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
28 drugs · 167 active trials
6 drugs · 136 active trials
6 drugs · 74 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 19 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Adebrelimab | Phase 2 | Phase 2 | 9 | 5 | 0 | 12 | 0 | — | — | 2018-11 |
| Bevacizumab | Phase 2 | Phase 2 | 4 | 4 | 0 | 14 | 0 | — | — | 2004-08 |
| Serplulimab | Phase 2 | Phase 2 | 4 | 3 | 0 | 4 | 0 | — | — | Dec 1, 2023 |
| FOLFOX Regimen | Phase 2 | Phase 2 | 3 | 1 | 0 | 8 | 0 | — | — | 2000-02 |
| Tremelimumab | Phase 2 | Phase 2 | 3 | 2 | 0 | 7 | 0 | — | — | Apr 28, 2016 |
| Futibatinib | Phase 2 | Phase 2 | 3 | 1 | 0 | 3 | 0 | — | — | Jun 1, 2021 |
| Gemcitabine | Phase 2 | Phase 2 | 2 | 1 | 0 | 8 | 0 | — | — | 1998-08 |
| Fludarabine | Phase 2 | Phase 2 | 2 | 1 | 0 | 5 | 0 | — | — | 2015-04 |
| Cabozantinib | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | Oct 22, 2018 |
| Palbociclib | Phase 2 | Phase 2 | 2 | 0 | 0 | 3 | 0 | — | — | Aug 17, 2015 |
| Trastuzumab Emtansine | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | 2014-10 |
| Adavosertib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Osimertinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Retifanlimab | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Sep 7, 2020 |
| Afatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 7 | 0 | — | — | May 29, 2014 |
| Cyclophosphamide | Phase 2 | Phase 2 | 1 | 0 | 0 | 6 | 0 | — | — | Dec 7, 2010 |
| Nedaplatin | Phase 2 | Phase 2 | 1 | 0 | 0 | 6 | 0 | — | — | 2010-01 |
| Sunitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 6 | 0 | — | — | Sep 25, 2006 |
| Aldesleukin | Phase 2 | Phase 2 | 1 | 1 | 0 | 4 | 0 | — | — | 1998-01 |
| Pemetrexed | Phase 2 | Phase 2 | 1 | 1 | 0 | 4 | 0 | — | — | 2005-09 |
| Dexamethasone | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2010-10 |
| Regorafenib | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2013-07 |
| Dasatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Fulvestrant | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Apr 7, 2022 |
| Metformin | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | 2012-06 |
| Sacituzumab Govitecan | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Dec 17, 2012 |
| Therapeutic Tumor Infiltrating Lymphocytes | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | May 15, 2020 |
| Anti-PD1 Monoclonal Antibody | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | 2026-09 |
| Binimetinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Capivasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Cixutumumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Sep 21, 2010 |
| Copanlisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Crizotinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Dabrafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Erdafitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Etoposide | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jul 13, 2024 |
| Fexagratinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Ipatasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Larotrectinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Patritumab Deruxtecan | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Sep 20, 2024 |
| Sapanisertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Taselisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Trametinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Vismodegib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Zongertinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jun 28, 2024 |
| Gefitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 9 | 0 | — | — | 2003-05 |
| Celecoxib | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 2000-07 |
| Erlotinib Hydrochloride | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 2001-12 |
| Everolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2009-09 |
| Decitabine | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 1999-10 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.